AC Immune (ACIU) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AC Immune has entered into an exclusive partnership with Takeda to develop and potentially commercialize an innovative Alzheimer’s treatment, ACI-24.060, which has shown promise in delaying the disease’s progression. The deal includes an upfront payment of $100 million to AC Immune, with future milestones that could total an additional $2.1 billion, plus tiered royalties on sales post-commercialization.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.